Compare RAVE & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAVE | LITS |
|---|---|---|
| Founded | 1958 | 2000 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.1M | 40.8M |
| IPO Year | 1995 | N/A |
| Metric | RAVE | LITS |
|---|---|---|
| Price | $2.59 | $1.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 24.6K | ★ 302.5K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.76 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $15,120,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.78 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.01 | $0.95 |
| 52 Week High | $3.75 | $3.03 |
| Indicator | RAVE | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 37.26 | 52.46 |
| Support Level | $2.34 | $1.17 |
| Resistance Level | $3.21 | $1.65 |
| Average True Range (ATR) | 0.13 | 0.07 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 39.32 | 83.91 |
Rave Restaurant Group Inc operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens. It operates restaurants under the brand name, Pizza Inn, and Pie Five Pizza Company. It has three operating segments. The Pizza Inn Franchising and Pie Five Franchising segments establish franchisees, licensees, and territorial rights. The corporate administration and other segments. The Pizza Inn Franchising segment accounts for the majority of the company's revenue. Geographically, it generates the majority of the revenue from the United States.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.